ABC | Volume 115, Nº1, July 2020

Short Editorial Macedo Tratamento de SRAA na obesidade Arq Bras Cardiol. 2020; 115(1):29-30 1. Ortega FB, Lavie CJ, Blair SN. Obesity and cardiovascular disease. Circ Res. 2016;118(11):1752-70. 2. Alpert, Martin A. et al. Obesity and cardiac remodeling in adults: mechanisms and clinical implications. Prog Cardiovasc Dis. 2018;61(2):114-23. 3. Good D, Morse SA, Ventura HO, Reisin E. Obesity, hypertension and the heart. J Cardiometabolic Syndr. 2009;3(3):168-72. 4. Frigolet ME, Torres N, Tovar AR. The renin-angiotensin system in adipose tissue and its metabolic consequences during obesity. J Nutrit Biochem. 2013;24(12):2003-15. 5. Kalupahana NS, Moustaid-Moussa W. The renin-angiotensin system: a link between obesity, inflammation and insulin resistance. Obesity Rev. 2012;13(2):136-49. 6. Garvey W T, Mechanick J I, Brett E M, Garber A J, Hurley D L, Jastreboff A M. et al. Reviewers of the AACE/ACE. Obesity Clinical Practice Guidelines. (2016). American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;Suppl 3:1-203. 7. Oliveira Jr SA, Muzili NA, Carvalho MR, Ota GE, Morais CS, Vieira LFC, et al. Bloqueio de receptors AT melhora o desempenho functional miocárdio na obesidade. Arq Bras Cardiol. 2020;115(1):17-28. 8. Alpert MA, Karthikevan K, Abdullah O, Ghadban R. Obesity and cardiac remodeling in adults: mechanisms and clinical implications. Prog Cardiovasc Dis. 2018;61(2):114-23. 9. Alpert MA, Omran J, Mehra A, Ardhanari S. Impact of obesity and weight loss on cardiac performance andmorphology in adults. Prog CardiovascDis. 2014;56(4):391–400. References This is an open-access article distributed under the terms of the Creative Commons Attribution License 30